Figure. Annual Out-of-Pocket Costs by Type of Care and Intensity of Pharmaceutical Claims for Women Prescribed Oral Breast Cancer Medications in 2018.

Data were extracted from the 2018 Marative MarketScan Database. Inpatient and outpatient claims are characterized by all claims that included International Statistical Classification of Diseases, Tenth Revision, Clinical Modification codes for invasive breast cancer. A total of 51.0% of the sample had no out-of-pocket costs for prescription drugs, and 16 women in the sample did not have any out-of-pocket costs for all modalities of care. Prescription drug claims characterized by all claims with a National Drug Code for a US Food and Drug Administration–approved drug for breast cancer if the patient also has an inpatient or outpatient diagnosis of cancer. All numbers are inflated to 2022 Bureau of Labor Statistics’ Consumer Price Index for Urban Consumers.